N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.
1. A compound of Formula I:
wherein:
R 1 is alkyl or cycloalkyl, each of which can be unsubstituted or substituted with from one to four independently selected electron-donating or electron-withdrawing groups;
R 2 , R v and R w are each independently hydrogen, alkyl, cycloalkyl, heterocyclo, aryl, or heteroaryl, which alkyl, cycloalkyl, heteroacylclo, aryl, or heteroaryl can be unsubstituted or substituted with from one to four independently selected electron-donating or electron-withdrawing groups, or R 2 , R v and R w are each independently an electron-donating or electron-withdrawing group;
R 3a , R 3b and R 4 are each independently hydrogen, an electron donating or electron-withdrawing group, or alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclo, heteroaryl, arylalkyl, heteroarylalkyl, or heterocycloalkyl, each of which can be unsubstituted or substituted with from one to four independently selected electron-donating or electron-withdrawing groups;
R 5 and R 6 are each independently H or alkyl; and
X′ is S or O;
or a pharmaceutically acceptable salt or prodrug thereof.
2. The compound of claim 1 , wherein:
R v and R w are both H;
R 4 is H;
R 5 is H;
R 6 is H; and
X′ is O;
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein:
R v and R w are both H;
R 1 is C1-C4 alkyl;
R 2 is hydrogen or C1-C4 alkyl;
R 3a is H;
R 3b is H, N 3 , or NCS;
R 4 is H;
R 5 and R 6 are both H;
X′ is O;
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein said compound is selected from the group consisting of:
5. The compound of claim 1 in the (R)-configuration.
6. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.
7. The composition of claim 6 , further comprising at least one neurological active agent in addition to said compound of Formula I.
8. The composition of claim 6 in oral administration form.
9. A compound of Formula Ia:
wherein:
R is R 2 or CH 2 X′R 5 , where X′ is O, S, or N—R 6a and R 6a is hydrogen, alkyl, or cycloalkyl;
R 1 is alkyl or cycloalkyl, each of which can be unsubstituted or substituted with from one to four independently selected electron-donating or electron-withdrawing groups;
R 2 is alkyl, cycloalkyl, aryl, five- or six-membered cyclic heterocyclic or heteroaromatic groups, or —X—Y—Z, where X and Y are O, S, or N—R 6 , and Z is R 6 , and where R 6 is hydrogen, alkyl, or cycloalkyl, each of which is unsubstituted or substituted with from one to four electron withdrawing or electron donating groups;
R 5 is alkyl, alkenyl, alkynyl, or arylalkyl, each of which is unsubstituted or substituted with from one to four electron donating or electron withdrawing groups;
R 3a R 3b , and R 4 are each independently hydrogen, an electron donating or electron-withdrawing group, or alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclo, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl, arylalkyloxy, arylalkylamino, arylalkylthio, heteroarylalkyloxy, heteroarylalkylamino, heteroarylalkylthio, heterocycloalkyloxy, heterocycloalkylamino, heterocycloalkylthio, arylaminooxy, heteroarylaminooxy, heterocycloaminooxy, aryloxyamino, heteroaryloxyamino, heterocyclooxyamino, arylalkyl, heteroarylalkyl, heterocycloalkyl, arylalkenyl, heteroarylalkenyl, heterocycloalkenyl, arylalkynyl, heteroarylalkynyl, heterocycloalkynyl, arylhydrazino, heteroarylhydrazino, heterocyclohydrazino, arylazo, heteroarylazo, heterocycloazo, arylalkylaminoalkyl, heteroarylalkylaminoalkyl, heterocycloalkylaminoalkyl, arylalkyloxyalkyl, heteroarylalkyloxyalkyl, heterocycloalkyloxyalkyl, each of which can be unsubstituted or substituted with from one, to four independently selected electron-donating or electron-withdrawing groups;
wherein at least one of R 3a and R 4 is not H;
and wherein at least one, or both, of R 3a and R 4 is a primary substituent selected from the group consisting of electron donating groups, electron-withdrawing groups, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclo, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl, arylalkyloxy, arylalkylamino, arylalkylthio, heteroarylalkyloxy, heteroaryalkylamino, heteroarylalkylthio, heterocycloalkyloxy, heterocycloalkylamino, heterocycloalkylthio, arylaminooxy, heteroarylaminooxy, heterocycloaminooxy, aryloxyamino, heteroaryloxyamino, heterocyclooxyamino, arylalkyl, heteroarylalkyl, heterocycloalkyl, arylalkenyl, heteroarylalkenyl, heterocycloalkenyl, arylalkynyl, heteroarylalkynyl, heterocycloalkynyl, arylhydrazino, heteroarylhydrazino, heterocyclohydrazino, arylazo, heteroarylazo, heterocycloazo, arylalkylaminoalkyl, heteroarylalkylaminoalkyl, heterocycloalkylaminoalkyl, arylalkyloxyalkyl, heteroarylalkyloxyalkyl, and heterocycloalkyloxyalkyl;
and which primary substituent is in turn optionally but preferably substituted with from one to four secondary substituents independently selected from the group consisting of electron-donating groups and electron-withdrawing groups;
or a pharmaceutically acceptable salt or prodrug thereof.
10. The compound of claim 9 , wherein R is R 2 .
11. The compound of claim 9 , wherein R is CH 2 X′R 5 .
12. The compound of claim 9 , wherein R 3b is H.
13. The compound of claim 9 , wherein R 1 is CH 3 .
14. The compound of claim 9 where R 2 is 2-furan, 2-thiazole, 2-oxazole, 2-pyridine, 2-pyrimidine, 2-pyridazine, N(H)OCH 3 , and N(CH 3 )OCH 3 , or N(H)N(H)CO 2 CH 3 .
15. The compound of claim 9 wherein X′ is O, and where R 5 is CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CHCH 2 , CH 2 CCH.
16. The compound of claim 9 where either or both of R 3a and R 4 are OCH 2 C 6 H 4 (m-F), OCF 3 , N 3 , CCCH 2 OCH 3 , CH 2 OCH 3 , (CH 2 ) 3 OCH 3 , C(N 2 )CF 3 , C(O)C 6 H 5 or CF 3 .
17. The compound of claim 9 , wherein said compound is a compound of Formula Ib:
wherein:
R is:
N(R′)OR′, CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH 2 OCH(CH 3 ) 2 , CH 2 OCD 3 , CH 2 OCD 2 CD 3 , CH 2 OCD 2 CH 3 , CH 2 OCD(CH 3 ) 2 , CH 2 OCD(CD 3 ) 2 , CH 2 OCF 2 H, CH 3 , CD 3 , CF 3 , CH 2 F, CH 2 CH 3 , (CH 2 ) 2 CH 3 , CH(CH 3 ) 2 , (CH 2 ) 3 CH 3 , or C(CH 3 ) 3 ;
each R′ is independently selected H or lower alkyl, unsubstituted or substituted with 1-3 electron-withdrawing or electron-donating groups;
X′ is a covalent bond or a linker that consist of one, two, or three connected atoms and which the atoms may or may not be substituted;
Y′ is an aromatic moiety, unsubstituted or substituted with 1-3 electron-withdrawing or electron-donating groups; and
Z′ is H, F, Cl, Br, I, CF 3 , CN, OCF 3 , or N 3 ;
or a pharmaceutically acceptable salt or prodrug thereof.
18. The compound of claim 9 , wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
19. The compound of claim 9 in the D-amino acid configuration, the L-amino acid configuration, or as a racemic mixture thereof.
20. The compound of claim 9 in the D-amino acid configuration.
21. A pharmaceutical composition comprising a compound of claim 9 in a pharmaceutically acceptable carrier.
22. The composition of claim 21 , further comprising at least one neurological active agent in addition to said compound of Formula Ia.
23. The composition of claim 21 in oral administration form.
24. The compound of claim 1 having the structure:
or a pharmaceutically acceptable salt thereof.